‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
(By Elizabeth Cooney for STAT) Their phones are ringing off the hook and their email inboxes are filling up with
Read More
Part D/Prescription Drugs
3 things to know about COVID-19 vaccine boosters
(By Erica Carbajal for Becker’s Hospital Review) Now that about 43 percent of the U.S. population has been fully vaccinated,
Read MoreFDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published June 10, 2021) The question of what would happen when
Read MoreHow Might Lowering the Medicare Age Affect Medicaid Enrollees?
(By MaryBeth Musumeci, Robin Rudowitz, and Tricia Neuman for Kaiser Family Foundation published June 10, 2021) President Biden’s FY 2022
Read MoreLouisiana bans insurers from controversial ‘white bagging’ practice
(By Morgan Haefner for Becker’s Hospital Review) A new law in Louisiana will bar health insurers from implementing a pharmacy
Read MoreKey Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2021
(By Juliette Cubanski and Anthony Damico for Kaiser Family Foundation published June 8, 2021) The Medicare Part D program provides
Read MorePharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds
(By Lev Facher for STAT) WASHINGTON — State lawmakers in Oregon have tried to lower high drug prices from nearly
Read MoreMedicare is supposed to cover the COVID-19 vaccine
Medicare is supposed to cover the COVID-19 vaccine itself with no out-of-pocket costs; however, providers can charge extra for additional
Read MoreWalmart adds prescription savings benefit
(By Maia Anderson for Becker’s Hospital Review) Walmart is now offering a prescription drug savings program to members of its Walmart+ program,
Read MoreFairness in Orphan Drug Exclusivity Act
The House passed the Fairness in Orphan Drug Exclusivity Act (H.R. 1629) to fix the nation’s orphan drug development rules
Read More